Abstract: Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that is the causative agent of adult T cell leukemia/lymphoma (ATL) and associated with multiorgan inflammatory disorders, including HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and uveitis. HTLV-1-infected T cells have been hypothesized to contribute to the development of these disorders, although the precise mechanisms are not well understood. HTLV-1 primarily infects CD4 
Introduction
Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus associated with chronic, persistent infection of human T cells. HTLV-1 infection is endemic in Japan, the Caribbean, and part of South America, Africa, the Middle East, and Melanesia [1] . Studies conducted in HTLV-1 endemic areas have demonstrated that HTLV-1 infection is associated with a variety of human diseases, including an aggressive mature T cell malignancy termed adult T-cell leukemia (ATL) [2] , which is defined as neoplastic growth of HTLV-1-infected T cells. HTLV-1 is also associated with non-neoplastic inflammatory conditions such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [3, 4] , uveitis [5] , Sjögren syndrome [6] , bronchoalveolitis, arthritis [7] , and polymyositis [8] , where high tissue concentrations of HTLV-1 infected T lymphocytes have been observed. Importantly, some patients have more than one of these HTLV-1-associated inflammatory conditions [9] .
Although HTLV-1-associated disorders have been extensively studied, the exact mechanism by which HTLV-1 induces these inflammatory conditions is not completely understood. The proviral load of HTLV-1 may contribute to development of HTLV-1-associated inflammatory conditions, since the number of HTLV-1-infected T cells circulating in the peripheral blood is higher in patients with HAM/TSP than in asymptomatic HTLV-1-infected individuals [10, 11] , and is even higher in the cerebrospinal fluid of patients with HAM/TSP [12] . In HAM/TSP patients, the proviral load correlates with not only the percentage of activated CD4 + T cells but also with that of HTLV-1-specific CD8 + cytotoxic T lymphocytes (CTLs) [11, 13] . These HTLV-1-specific CTLs produce various cytokines, such as IFN-γ and TNF-α, that may suppress viral replication and kill infected cells and/or promote bystander activation and killing of nearby resident cells in the central nervous system (CNS) [14] [15] [16] [17] . In addition, increased viral expression, particularly of the transactivating viral gene encoding HTLV-1 Tax, has also been hypothesized to play a role in HTLV-1 disease progression [11, 12] . Transgenic mice expressing HTLV-1 Tax develop an inflammatory arthropathy [18] , and transgenic rats expressing HTLV-1 env-pX develop destructive arthropathy, Sjögren syndrome, vasculitis, and polymyositis [19] . These findings support the hypothesis that HTLV-1 tax is one of the exogenous retrovirus genes responsible for immune dysregulation.
HTLV-1 Tax is a transactivator/oncoprotein that has potent effects on infected T cells, including activation of nuclear factor(NF)-κB [20] with subsequent enhancement of cell activation and proliferation and expression of various cellular genes, such as IL-2 [21] , the α-chain of the IL-2 receptor (IL-2Rα) [22] , IL-15 [23] , and IL-15Rα [24] . Such virus-induced intracellular activation may directly contributes to T cell activation and the ex vivo T cell proliferation observed in patients with HAM/TSP [25] . These findings suggest that invasion by HTLV-1-infected T cells, together with viral gene expression and cellular-signaling mechanisms, trigger a strong virus-specific immune response and increased proinflammatory cytokine production, leading to CNS inflammation and autologous tissue damage. However, the precise mechanisms underlying the induction of immune activation by HTLV-1-infected T cells are not well understood.
HTLV-1 and Regulatory T Cells
The recent discovery of regulatory T cells (Treg cells) has generated new opportunities for and increased interest in elucidating the above mentioned mechanisms. In healthy individuals, the Treg cells, a subset of CD4 + CD25 + T cells, play a key role in maintaining immune system homeostasis by suppressing the proliferation of and cytokine production by pathogenic T cells [26] . Although Treg cells are phenotypically similar to activated T cells, they can be identified ex vivo by their intracellular expression of the transcriptional regulator Foxp3 [27] , which is critical in the development and functioning of Treg cells in both mice and humans. Significant reductions in Foxp3 expression and/or Treg cell function have been observed in patients with several types of human autoimmune diseases [28] , suggesting that defects in Foxp3 expression and/or Treg functioning may precipitate loss of immunological tolerance. CD4 [30, 34] . Notably, overexpression of HTLV-1 Tax has been observed to reduce Foxp3 expression and inhibit the suppressive function of Treg cells in vitro [30] . Furthermore, because of a Tax-induced defect in TGF-β signaling, Foxp3 expression was decreased and Treg functions were impaired in patients with HAM/TSP [35] . Recently, significantly decreased numbers of CD4
Treg cells were observed in transgenic mice expressing HTLV-1 Tax that develop an inflammatory arthropathy [36] . In addition, increased viral expression of the HTLV-1 bZIP factor (HBZ) gene encoding the minus strand of HTLV-1 has also been suggested to play a role in HTLV-1 disease progression [37] , and CD4 [39, 40] . Therefore, it has been hypothesized that ATL cells may be derived from Treg cells [41] . Interestingly, some ATL cells exhibit immunosuppressive functions similar to those of Treg cells, which may contribute to clinically observed cellular immunodeficiency in ATL patients [41] [42] [43] , although some of these ATL cells lose this regulatory function [44] . The chemokine receptor CCR4 has recently been found to be expressed on HTLV-1-infected leukemia cells in ATL patients [51] . Because CCR4 is known to be selectively expressed on Treg and Th2 cells [51] [52] [53] (Figure 1 ) and because most ATL cells express high levels of Foxp3, it has been hypothesized that ATL cells may be derived from Treg cells [41] . Although it has been demonstrated that CD4 + CD25 + T cells in HAM/TSP patients exhibit reduced Foxp3 expression and Treg suppression [30] [31] [32] [33] and that HTLV-1-infected CD4 + T cells in HAM/TSP patients produce Th1 cytokines (IFN-γ) [16, 30] , it has also been observed that CCR4 selectively overexpresses on HTLV-1-infected T cells in HAM/TSP patients [54] . Furthermore, the majority of CD4 [55] . Therefore, it would be of interest to build on this finding by confirming whether this newly defined unique T cell subset, which has been observed in both HAM/TSP and SLE patients, is found in both these patient groups and can be functionally deregulated in other immunological diseases.
Although most CD4 T cell subset has been found to be high in HAM/TSP patients but low in ATL patients [54] . This differential T HAM /Treg ratio in HTLV-1-infected T cells may be associated with the differential immune responses observed between HAM/TSP and ATL patients (Figure 3) . ATL patients tend to have very low numbers of Tax-specific CD8 + T cells in peripheral blood mononuclear cells (PBMCs) and to develop opportunistic infections [57, 58] , while HAM/TSP patients tend to have high numbers of Tax-specific CD8 + CTLs [11, 12, 14, 59] . As CD4 [62, 63] . These findings support the hypothesis that HTLV-1 tax may be one of the exogenous retrovirus genes responsible for immune dysregulation through its interference in the equilibrium between inflammation and tolerance.
This hypothesis is currently being tested as a means of elucidating the precise molecular mechanisms by which HTLV-1 influences the fate and function of CD4 
Mechanisms Underlying Increased HTLV-1 Tax Expression in HAM/TSP Patients
As described above, higher levels of HTLV-1 Tax expression have been observed in HAM/TSP patients [11] , and a correlation between Tax expression and disease risk [64] has been identified. Both findings, together with experimental evidence [65] and theoretical justification [66] for selective proliferation of HTLV-1 expressing T cells in vivo, indicate that increased HTLV-1 provirus expression may play an important role in the pathogenesis of HAM/TSP. However, the molecular mechanisms underlying the increased levels of HTLV-1 provirus expression in HAM/TSP patients are not understood. Evidence continues to accumulate that the genomic integration site of HTLV-1 provirus affects the level of provirus expression. Continued accumulation of evidence is aided by the availability of the human genome sequence, which has enabled large-scale research into HTLV-1 integration sites. This research has demonstrated that the provirus integration sites of HTLV-1 in vivo are not randomly distributed within the human genome but rather associated with transcriptionally active regions [67, 68] ; that the frequent integration into these transcription units is associated with increased levels of provirus expression; and, importantly, that the increased number of integration sites in transcription units is associated with HAM/TSP [68] . Future research should endeavor to elucidate the mechanisms underlying the immune dysregulation observed in HAM/TSP patients. T cells, which may contribute to the development of HAM/TSP. As such, these results support the hypothesis that HTLV-1 is one of the exogenous retrovirus genes responsible for immune dysregulation through its interference in the equilibrium maintained among host immune responses. Because the majority of immune disorders are of unknown etiology, the discovery of HTLV-1 and its association with inflammatory conditions has greatly enhanced our understanding of the pathogenic mechanisms underlying organ-specific immune disorders. Further investigation of the mechanism underlying HTLV-1 action in the immune system may result in identification of new molecular pathways that will further elucidate the basic mechanisms underlying immune-mediated disorders.
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